Corstasis Therapeutics, a biopharmaceutical company focused on developing new treatments for respiratory illnesses, has announced the appointment of Sanjeev Narula to its Strategic Advisory Board. Narula brings extensive experience leading financial and strategic initiatives within the healthcare and pharmaceutical sectors. His addition is expected to support Corstasis as it advances its clinical development programs and expands its role in the respiratory disease treatment market.
Health Technology Insights: Premier Anesthesia Partners with Salina Regional Health Center For Surgical Excellence
Mr. Narula served as the first Chief Financial Officer of Viatris, which he joined in 2020 when the company was formed through the combination of Mylan and Upjohn, a division of Pfizer Inc. Prior to Viatris, he served as Chief Financial Officer at Upjohn, overseeing finance, procurement and business technology for all functions of the business, and held several other financial leadership positions during his 16 years at Pfizer.
Health Technology Insights: Humana Speeds Up Care by Easing Prior Approvals
“We are excited to welcome Sanjeev to our Strategic Advisory Board,” said Benjamin Esque, Chairman and Chief Executive Officer of Corstasis Therapeutics Inc. “His experience in guiding companies through critical stages of development and growth will be instrumental as we strive to deliver effective treatments to patients with serious respiratory conditions.”
Corstasis is currently focused on advancing its lead drug candidate, CST-103, through clinical trials targeting bronchiectasis, a chronic respiratory disease. With Narula’s expertise, the company aims to strengthen its financial and strategic planning to achieve long-term success in a dynamic and competitive market. This appointment highlights Corstasis’ commitment to building a strong advisory team to support its mission of delivering vital therapies to patients with chronic respiratory illnesses.
Health Technology Insights: NationsBenefits, Heritage Grocers Advance Food-as-Medicine
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
